ReNeuron stem cell trial gets go-ahead
ReNeuron, the Aim-listed biotech company, has been given the go-ahead to start a ground-breaking clinical trial to assess whether stem cell therapy can help patients disabled by stroke.
[Read the full article here]Related News:
UK firm gets final green light for stem cell trial
UPDATE 1-UK firm gets final green light for stem cell trial
UK firm begins stem cell trial